Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data

TIPRANKS04-12

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426659227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-12 13:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426659227","market":"fut","top_or_hot":-1,"title":"Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data","media":"TIPRANKS","content":"<div>\n<p>Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-12 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FUSN","symbol_name":"Fusion Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral","article_id":"2426659227","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2426659227","pubTimestamp":1712900267,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FUSN":"Fusion Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Fusion Pharmaceuticals：在收购和有希望的前列腺癌治疗数据中的市场表现评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FUSN":1},"content_text":"Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426659227"}